Cancer Therapies

Phase II Trial of Liposomal Anthracycline Initiated for Breast Cancer Treatment

Published in Breast Cancer Weekly, April 15th, 2000

Aronex Pharmaceuticals, Inc. (ARNX), The Woodlands, Texas, announced the initiation of a Phase II clinical trial evaluating the use of Annamycin in refractory breast cancer patients, who overexpress P-glycoprotein (PGP) in the tumor cell.

It is now widely accepted that PGP acts as one of the principal mechanisms to transport drugs out of the tumor cells, rendering the drugs ineffective. Once resistance develops, it often extends to other chemotherapeutic agents, resulting in multidrug-resistant tumors.

Annamycin is a liposomal anthracycline designed to treat a broad range of cancers, including those that exhibit multidrug resistance, a limitation...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Breast Cancer Weekly

Source: Breast Cancer Weekly (2000-04-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry